Literature DB >> 3498522

Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias.

M T Mitjavila1, J L Villeval, P Cramer, A Henri, J Gasson, G Krystal, M Tulliez, R Berger, J Breton-Gorius, W Vainchenker.   

Abstract

Erythroid colonies from five patients with an early erythroblastic leukemia were obtained in "serum-free" cultures in the presence or absence of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and homogeneous native erythropoietin (Epo). Erythroid colonies with abnormal morphology and karyotype could be grown in different culture conditions. Their erythroid nature was ascertained by the presence of carbonic anhydrase I and glycophorin A. Leukemic erythroid progenitors strongly differed from normal progenitors in that spontaneous colonies were always obtained, sometimes with an extremely high plating efficiency (up to 5.7%). Colonies were found to be autonomous from exogenous hematopoietic growth factors because they were still obtained with a high plating efficiency at an average of one cell per culture in the absence of any added growth factor. No evidence for an autocrine secretion of Epo or GM-CSF emerged because Epo or GM-CSF could not be detected by biologic or radioimmunologic assays from the culture supernatant or cellular extracts of the leukemic cells and that Epo or GM-CSF antibodies did not block autonomous growth. In all cases, however, hematopoietic growth factors increased the plating efficiency of the abnormal erythroid progenitors. In the two "de novo" leukemias, leukemic erythroid progenitors responded primarily to Epo, whereas in the three other patients' (chronic myeloid leukemia) blast crisis they responded maximally to GM-CSF plus Epo. Recombinant erythroid-potentiating activity had no effect in any of these cases. These results suggest that the leukemic erythroid clonogenic cells arise from expansion of erythroid progenitors at different levels of differentiation (ie, CFU-E or BFU-E, depending upon the disease) and that autonomous growth is not related to a secretion of Epo or GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498522

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro.

Authors:  M T Mitjavila; J P Le Couedic; N Casadevall; S Navarro; J L Villeval; A Dubart; W Vainchenker
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

Review 2.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

3.  Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro.

Authors:  W E Berdel; D Oberberg; B Reufi; E Thiel
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

4.  Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Authors:  G E Verhoef; P Zachée; A Ferrant; H Demuynck; D Selleslag; L Van Hove; F Deckers; M A Boogaerts
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

5.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

6.  A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.

Authors:  Pierre Fenaux; Valeria Santini; Maria Antonietta Aloe Spiriti; Aristoteles Giagounidis; Rudolf Schlag; Atanas Radinoff; Liana Gercheva-Kyuchukova; Achilles Anagnostopoulos; Esther Natalie Oliva; Argiris Symeonidis; Mathilde Hunault Berger; Katharina S Götze; Anna Potamianou; Hari Haralampiev; Robert Wapenaar; Iordanis Milionis; Uwe Platzbecker
Journal:  Leukemia       Date:  2018-03-30       Impact factor: 11.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.